KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Consolidated Net Income rose 5.58% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.90% up from last year.
  • Per Nektar Therapeutics' latest filing, its Consolidated Net Income stood at -$35.0 million for Q3 2025, which was up 10.76% from -$39.2 million recorded in Q2 2025.
  • Nektar Therapeutics' Consolidated Net Income's 5-year high stood at $7.2 million during Q4 2024, with a 5-year trough of -$159.1 million in Q2 2022.
  • For the 3-year period, Nektar Therapeutics' Consolidated Net Income averaged around -$46.9 million, with its median value being -$42.1 million (2023).
  • In the last 5 years, Nektar Therapeutics' Consolidated Net Income slumped by 56.90% in 2021 and then soared by 117.19% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Consolidated Net Income (Quarterly) stood at -$146.9 million in 2021, then surged by 54.66% to -$66.6 million in 2022, then spiked by 36.82% to -$42.1 million in 2023, then spiked by 117.19% to $7.2 million in 2024, then rose by 5.58% to -$35.0 million in 2025.
  • Its Consolidated Net Income stands at -$35.0 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$46.4 million for Q1 2025.